Classify urinary incontinence; discuss its evaluation and treatment

Definition: Urinary incontinence (UI) is the involuntary loss of urine that is objectively demonstrable, in an amount or frequency sufficient to be a social and/or health problem.

Prevalence: About one in three women and 15–20% of men above 65 years are affected; rises to 60–80% in nursing homes. In women with comorbidity, cognitive or physical impairment, or polypharmacy, prevalence may reach 70–80%.

Ageing is not the cause. Age-related changes only predispose: reduced bladder capacity, higher residual urine, more involuntary detrusor contractions, fall in urethral closure pressure (women), prostatic enlargement (men), and loss of the normal night-time rise in vasopressin with higher ANP causing nocturnal polyuria.

Consequences: skin breakdown, recurrent UTI, falls and fractures (especially nocturnal), isolation, depression, dependency, caregiver strain, and institutionalisation.

Physiological classification (two basic faults): (i) failure to store — overactive or poorly compliant bladder, or weak outlet; (ii) failure to empty — poorly contractile bladder, or increased outlet resistance.

By time course: Acute (transient) incontinence — sudden onset with an acute illness or drug, resolves when the cause is treated; Persistent incontinence — unrelated to acute illness, continues over time.

Persistent UI has four basic clinical types (they overlap in the same patient):

Mixed incontinence (stress + urge) is the commonest pattern in older women. Frail older patients typically combine urge incontinence with functional disability.

Special subtype — DHIC (detrusor hyperactivity with impaired contractility): involuntary contractions but emptying of less than one-third of bladder volume; patients strain to void and are difficult to treat because of retention. Very high-yield.

Overactive bladder (OAB) is a symptom syndrome (urgency ± frequency >8/24 h ± nocturia), with or without incontinence; ~30% of women and ~40% of men aged ≥75 report these symptoms.

Case-finding first — patients rarely volunteer it. Ask: "Do you have trouble with your bladder?", "Do you ever lose urine when you don't want to?", "Do you wear padding in case you lose urine?"

Basic evaluation in ALL patients (four components): focused history (with bladder record), targeted physical examination, urinalysis, and post-void residual (PVR).

History: onset and type, frequency/timing/volume, irritative vs voiding symptoms, fluid and caffeine pattern, obstetric/surgical/GU history, comorbidity (diabetes, heart failure, neurological disease), drug review, bowel habit, environment, and the most bothersome symptom.

Bladder diary / voiding chart for 3 days characterises the pattern and monitors response to treatment.

Examination: mobility and dexterity, cognition and mood, focal neurology and sacral reflexes, abdomen for distended bladder, rectal for impaction/tone/prostate, and pelvic examination for atrophic vaginitis and prolapse (cystocele grading).

Urinalysis: persistent microscopic haematuria (>5 RBC/hpf) without infection needs cytology and cystoscopy. Bacteriuria in a community patient with new or worsening incontinence should be treated before further evaluation; in nursing-home residents, eradicating bacteriuria does not improve chronic stable incontinence.

PVR: by bladder ultrasound or in–out catheter. >200 mL is abnormal and warrants further evaluation. PVR may be omitted in a carefully selected patient with pure stress or pure urgency symptoms, no voiding difficulty and no risk factor for retention.

Uroflowmetry is a useful non-invasive screen in older men: peak flow <10 mL/s on a voided volume >150 mL suggests obstruction or impaired contractility.

Referral criteria for urology/gynaecology/urodynamics: recent pelvic surgery or irradiation (<6 months), ≥2 symptomatic UTIs in 12 months, risk factors for bladder cancer (new irritative symptoms, heavy smoking, aniline dye exposure), marked pelvic prolapse, significant retention, prostatic nodule, or failure of an adequate therapeutic trial.

Step 1 — correct reversible factors (mnemonic DRIP: Delirium; Restricted mobility/ Retention; Infection, Inflammation, Impaction; Polyuria, Pharmaceuticals). Relief of faecal impaction alone may restore continence.

Step 2 — behavioural therapy for everyone. Patient-dependent: pelvic floor (Kegel) exercises — the single most effective component — bladder training, bladder retraining. Caregiver-dependent: scheduled toileting, habit training, prompted voiding (25–40% of nursing-home residents become dry by day).

Step 3 — drugs, by type:

Urge/OAB: antimuscarinics — darifenacin 7.5–15 mg, solifenacin 5–10 mg, tolterodine, fesoterodine, oxybutynin, trospium. Full effect takes 1–2 months; warn about dry mouth, constipation, glaucoma, reflux and cognitive impairment/delirium.

Men with BPH-related irritative symptoms: α-blocker (tamsulosin 0.4 mg, alfuzosin 10 mg, silodosin 4 mg) ± antimuscarinic; add a 5-α-reductase inhibitor if prostate >30 g.

Stress: no drug is licensed; α-agonist (pseudoephedrine) ± topical oestrogen, or duloxetine, are off-label options.

Atrophic vaginitis: topical vaginal oestrogen only — oral oestrogen is ineffective and may worsen incontinence.

Refractory nocturia: low-dose desmopressin with close sodium monitoring — hyponatraemia risk is high in the elderly.

Step 4 — devices and surgery: pessary for prolapse; periurethral bulking or sling for intrinsic sphincter deficiency; colposuspension/autologous fascial sling for stress UI; TURP or other prostatic surgery for obstruction; artificial urinary sphincter for post-prostatectomy sphincter damage; intradetrusor botulinum toxin and sacral neuromodulation (S3) for refractory OAB.

Catheters only for specific indications. Condom catheter only for intractable incontinence in a dependent man without retention; intermittent catheterisation keeps volumes <400 mL; chronic indwelling catheters are a last resort.

Supportive care throughout: education, accessible toilets and toilet substitutes, timing of diuretics, fluid and caffeine advice, absorbent pads (never as the first response), and meticulous skin care.

Prognosis: UI is curable or controllable in most older patients with adequate mobility and cognition; when not curable it can always be managed to keep the patient comfortable and the caregiver's burden low.

AUA/SUFU Idiopathic Overactive Bladder Guideline 2024 replaced the older stepped "first/second/third-line" framework with shared decision-making; patients may move directly to any treatment tier. Behavioural therapy remains the foundation but need no longer be exhausted before advanced therapy.

The same guideline explicitly recommends frailty assessment (Clinical Frailty Scale) and anticholinergic-burden review before prescribing antimuscarinics, and prefers β3-agonists (mirabegron, vibegron) in older and cognitively vulnerable adults.

Vibegron (β3-agonist) received FDA approval in December 2024 for men with OAB symptoms already on pharmacological therapy for BPH, based on the phase-3 COURAGE / URO-901-3005 trial in ~1100 men — a group previously restricted to antimuscarinics.

AUA/GURS/SUFU Incontinence after Prostate Treatment Guideline (2024) and AUA/SUFU/AUGS Genitourinary Syndrome of Menopause Guideline (2025) formalised, respectively, post-prostatectomy stress UI management and low-dose vaginal oestrogen for urogenital atrophy.

Cochrane and guideline-level evidence continues to place supervised pelvic floor muscle training first for stress and mixed UI in women — around an eight-fold higher chance of cure or improvement versus no treatment.

Indian data: LASI Wave 1 (2017–18, 72,250 participants aged ≥45) shows UI is strongly linked to insomnia, sarcopenia, diabetes and household solid-fuel smoke; self-report grossly under-estimates true prevalence, confirming that active case-finding, not passive reporting, is the Indian priority. Continence care is now embedded in NPHCE geriatric clinics and district geriatric units.

DRIP — Delirium · Restricted mobility, Retention · Infection, Inflammation, Impaction · Polyuria, Pharmaceuticals (the textbook's own mnemonic for reversible causes).

DIAPPERS — Delirium, Infection, Atrophic vaginitis/urethritis, Pharmaceuticals, Psychological, Excess urine output, Restricted mobility, Stool impaction (classic alternative; quote both).

Four persistent types — "S-U-O-F": Stress, Urge, Overflow, Functional.

Normal bladder capacity 300–600 mL; first urge 150–300 mL; filling pressure <15 cm H₂O.

Frequency = >8 voids/24 h or voiding more often than 2-hourly; nocturia = ≥2 voids at night.

PVR >200 mL abnormal; keep intermittent catheter volumes <400 mL; Qmax <10 mL/s abnormal.

Prompted voiding success 25–40%; nursing-home prevalence 60–80%; DHIC = emptying <1/3 of bladder volume. Examiner traps — (1) Do not say ageing causes incontinence; say ageing predisposes. (2) Do not order urodynamics routinely; it is for selected patients only. (3) Do not forget PVR — overflow incontinence is easily missed on examination. (4) Do not treat asymptomatic bacteriuria in a stable nursing-home resident. (5) Do not prescribe oral oestrogen. (6) Remember DHIC — antimuscarinics can precipitate retention in these patients. 15-second answer skeleton: Definition → prevalence → ageing predisposes (not causes) → two basic faults (storage/emptying) → acute vs persistent → four types + mixed + DHIC → evaluation: 4 basics (history, examination, urinalysis, PVR) + selected further tests + referral criteria → treatment: DRIP → behavioural → drugs by type → devices/surgery → catheters last → supportive care → prognosis.

UI = involuntary, objectively demonstrable urine loss that is a social or health problem.

Four persistent types: stress, urge, overflow, functional — overlap is the rule.

Mixed (stress + urge) is commonest in older women; urge + functional in frail elders.

Reversible causes: DRIP / DIAPPERS.

Basic evaluation = history + examination + urinalysis + PVR. PVR >200 mL is abnormal.

Pelvic floor muscle exercises give the greatest benefit of all behavioural measures.

Antimuscarinics take 1–2 months for full effect; β3-agonists are safer in the frail elderly.

Topical, never oral, oestrogen for atrophic vaginitis.

DHIC = detrusor overactivity + impaired contractility; patients strain and retain.

Catheters are for specific indications, never for convenience.